Skip to main content

Day: April 26, 2021

Faurecia : déclaration des transactions sur actions propres du 19 avril 2021 au 23 avril 2021

Nanterre, le 26 avril 2021 Déclaration des transactions sur actions propres Période du 19 avril 2021 au 23 avril 2021(article 241-4, I Règlement Général de l’Autorité des Marchés Financiers et position-recommandation de l’Autorité des Marchés Financiers DOC-2017-04) Présentation agrégée par jour et par marchéNom de l’émetteur Code identifiant de l’émetteur (code LEI) Jour de la transaction Code identifiant de l’instrument financier Volume total journalier (en nombre de titres) Prix pondéré moyen journalier d’acquisition Code identifiant marchéFAURECIA 969500F0VMZLK2IULV85 19/04/2021 FR0000121147 12 000 47,1930 XPARFAURECIA 969500F0VMZLK2IULV85 19/04/2021 FR0000121147 5 000 47,1968 CEUXFAURECIA 969500F0VMZLK2IULV85 19/04/2021 FR0000121147 3 000 47,1870 TQEXFAURECIA 969500F0VMZLK2IULV85 20/04/2021 FR0000121147 6...

Continue reading

Genovac Antibody Discovery Launches in NDSU Research and Technology Park

Fargo, North Dakota, April 26, 2021 (GLOBE NEWSWIRE) —Genovac Antibody Discovery has launched in the United States following a management buyout of an antibody discovery business unit owned by Aldevron, a U.S.-based contract manufacturing organization. The unit, which was established and operates in Freiburg, Germany, is now headquartered in Fargo, N.D. Brian Walters, who had been serving as the president of Aldevron’s Antibody Discovery Group, led the management buyout and is now Genovac’s president and CEO. Genovac is a contract research organization that discovers and develops antibodies for therapeutic, diagnostic and research and development market segments, with clients in North America, Europe, Australia and Asia. The company’s core technology, genetic immunization, enables rapid antibody discovery against biopharma’s...

Continue reading

REITIR: Birting grunnlýsingar

Reitir fasteignafélag hf., kt. 711208-0700, Kringlunni 4-12, 103 Reykjavík, hefur birt grunnlýsingu í tengslum við útgáfuramma skuldabréfa. Grunnlýsingin er dagsett 26. apríl 2021, staðfest af Fjármálaeftirlitinu, gefin út á íslensku og birt á vefsíðu Reita, www.reitir.is/fjarfestar. Grunnlýsinguna má nálgast á vefsíðunni næstu tíu ár frá staðfestingu hennar og hjá útgefanda á skrifstofu félagsins að Kringlunni 4-12 í Reykjavík. Nánari upplýsingar um Reiti fasteignafélag hf. og útgáfurammann má finna í framangreindri grunnlýsingu. Fossar markaðir hf. veittu Reitum ráðgjöf við gerð grunnlýsingarinnar. Nánari upplýsingar veitir: Einar Þorsteinsson, fjármálastjóri, á netfanginu einar@reitir.is eða í síma 669 4416. ViðhengiGrunnlýsing Reita fasteignafélags hf. – 26.4.2021

Continue reading

PRESS RELEASE RELATING TO THE FILING OF THE DRAFT SIMPLIFIED TENDER OFFER – TARKETT PARTICIPATION

PRESS RELEASE RELATING TO THE FILING OF THE DRAFT SIMPLIFIED TENDER OFFER FOR THE SHARES OF THE COMPANY INITIATED BY TARKETT PARTICIPATION PRESENTED BY ROTHSCHILD MARTIN MAUREL  PRESENTING BANK and BNP PARIBAS CREDIT AGRICOLE CORPORATE INVESTMENT BANK   SOCIETE GENERALE   PRESENTING AND GUARANTEEING BANKOFFER PRICE: 20 Euros per Tarkett share DURATION OF THE OFFER: 21 trading days This press release has been established by Allianz SE and released in accordance with the provisions of article 231-16 of the general regulation of the Autorité des marchés financiers (the “AMF”). This offer and the draft offer document remain subject to the review of the AMF. IMPORTANT NOTICE In accordance with Article L. 433-4(II) of the French Monetary and Financial Code and Articles 237-1 and following of the AMF’s general regulation, in the event...

Continue reading

ERRATUM – LUMIBIRD: 2021 FIRST-QUARTER REVENUES

Lannion, April 26, 2021 – 5:45pm 2021 FIRST-QUARTER REVENUES THE LUMIBIRD GROUP, THE EUROPEAN LEADER FOR LASER TECHNOLOGIES, ACHIEVED 54% CONSOLIDATED REVENUE GROWTH IN THE FIRST QUARTER OF 2021 TO €33.8M, DRIVEN BY THE INTEGRATION OF ELLEX’S LASER AND ULTRASOUND ACTIVITIES. ON A PRO-FORMA BASIS1, REVENUES ARE UP +3.2% (+5.0% AT CONSTANT EXCHANGE RATES), REFLECTING THE GRADUAL UPTURN IN BUSINESS COMPARED WITH A FIRST QUARTER OF 2020 THAT WAS STILL RELATIVELY UNAFFECTED BY THE IMPACTS OF THE CRISIS. Consolidated revenues (unaudited)Revenues (€m) 2021 2020 Reported change pro forma 2020 1 Pro forma 1 changeFirst quarter 33.8 21.9 +54% 32.7 +3,2%of which          Photonics 14.6 13.3 +9.0% 13.3 +9.0%Medical 19.2 8.6 +124% 19.4 -1.1%The LUMIBIRD Group’s consolidated revenues came to €33.8m at March 31, 2021, up 54%. Compared...

Continue reading

ERRATUM – LUMIBIRD : CHIFFRE D’AFFAIRES DU 1ER TRIMESTRE 2021

Lannion, le 26/04/2021 – 17h45 CHIFFRE D’AFFAIRES DU 1ERTRIMESTRE 2021 LE GROUPE LUMIBIRD, LEADER EUROPÉEN DES TECHNOLOGIES LASER, ENREGISTRE UNE CROISSANCE DE 54% DE SON CHIFFRE D’AFFAIRES CONSOLIDÉ AU 1ERTRIMESTRE 2021, À 33,8 M€, SOUS L’EFFET DE L’INTÉGRATION DES ACTIVITÉS LASERS ET ULTRASONS D’ELLEX. EN PRO-FORMA1LE CHIFFRE D’AFFAIRES AUGMENTE DE 3,2% (+5,0% À TAUX DE CHANGE CONSTANT), REFLÉTANT LA REPRISE PROGRESSIVE DE L’ACTIVITÉ PAR RAPPORT À UN 1ERTRIMESTRE 2020 QUI ÉTAIT ENCORE PEU TOUCHÉ PAR LES EFFETS DE LA CRISE. Chiffre d’affaires consolidé (non audité)Chiffre d’affaires (M€) 2021 2020 Variation publiée pro forma 2020 1 Variation pro forma 1Premier trimestre 33,8 21,9 +54% 32,7 +3,2%dont          Photonique 14,6 13,3 +9,0% 13,3 +9,0%Médical 19,2 8,6 +124% 19,4 –1,1%Le chiffre d’affaires consolidé...

Continue reading

GOGL – Preliminary results of the Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. 26 April 2021, Hamilton, Bermuda Reference is made to the stock exchange release by Golden Ocean Group Limited (NASDAQ and OSE: GOGL) (the “Company”) on 15 April 2021 regarding commencement of a subsequent offering of up to 2,710,377 new shares in the Company at a subscription price of NOK 53.00 per share, raising gross proceeds of up to approximately NOK 143.6 million (the “Subsequent Offering“). The subscription period in the Subsequent Offering expired today on 26 April 2021 at 16:30 hours...

Continue reading

Forløb af ordinær generalforsamling den 26. april 2021 i Investeringsforeningen Danske Invest Select

Beretningen og årsrapporten for 2020 for Investeringsforeningen Danske Invest Select blev godkendt på dagens ordinære generalforsamling. Samtidig blev de foreslåede udbytter for 2020 vedtaget. De samlede udbytter for foreningen blev 2 mia. kroner. Til foreningens bestyrelse blev direktør Agnete Raaschou-Nielsen, advokat Bo Holse, direktør Birgitte Brinch Madsen, direktør Lars Fournais og direktør Jens Peter Toft genvalgt. Bestyrelsen konstituerede sig efterfølgende med Agnete Raaschou-Nielsen som formand og Bo Holse som næstformand. Herudover valgtes Price Waterhouse Coopers Statsautoriseret Revisionspartnerselskab som revisor for foreningen. Bestyrelsen havde fremsat forslag om forskellige tilpasninger af vedtægterne. Generalforsamlingen tilsluttede sig samtlige fremsatte forslag. Ændringerne afventer Finanstilsynets godkendelse og forventes...

Continue reading

Forløb af ordinær generalforsamling den 26. april 2021 i Investeringsforeningen Danske Invest

Beretningen og årsrapporten for 2020 for Investeringsforeningen Danske Invest blev godkendt på dagens ordinære generalforsamling. Samtidig blev de foreslåede udbytter for 2020 vedtaget. De samlede udbytter for foreningen blev 3,2 mia. kroner. Til foreningens bestyrelse blev direktør Agnete Raaschou-Nielsen, advokat Bo Holse, direktør Birgitte Brinch Madsen, direktør Lars Fournais og direktør Jens Peter Toft genvalgt. Bestyrelsen konstituerede sig efterfølgende med Agnete Raaschou-Nielsen som formand og Bo Holse som næstformand. Herudover valgtes Price Waterhouse Coopers Statsautoriseret Revisionspartnerselskab som revisor for foreningen. Bestyrelsen havde fremsat forslag om forskellige tilpasninger af vedtægterne. Generalforsamlingen tilsluttede sig samtlige fremsatte forslag. Ændringerne afventer Finanstilsynets godkendelse og forventes...

Continue reading

Mandatory Notice of Trade in IDEX Biometrics – 26 April 2021

James Allen (Jamie) Simms, CFO of IDEX Biometrics ASA, has today accepted a grant of 2,750,000 incentive subscription rights to shares in IDEX. The grant was made for no consideration. IDEX shares have ISIN NO0003070609. For further information contact:Marianne Bøe, Investor RelationsE-mail: marianne.boe@idexbiometrics.comTel: + 47 9180 0186 About IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX and Nasdaq: IDBA) is a leading provider of fingerprint identification technologies offering simple, secure, and personal touch-free authentication for all.  We help people make payments, prove their identity, gain access to information, unlock devices, or gain admittance to buildings with the touch of a finger. We invent, engineer, and commercialize these secure, yet incredibly user-friendly solutions.  Our total addressable market represents a fast...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.